The effect of chemotherapeutic agents on tumor vasculature in subcutaneous and orthotopic human tumor xenografts

[1]  M. Shoichet,et al.  Blood vessel hyperpermeability and pathophysiology in human tumour xenograft models of breast cancer: a comparison of ectopic and orthotopic tumours , 2012, BMC Cancer.

[2]  R. Kerbel,et al.  Mouse models of advanced spontaneous metastasis for experimental therapeutics , 2011, Nature Reviews Cancer.

[3]  R. Kerbel,et al.  Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. , 2008, Cancer cell.

[4]  N. Hylton,et al.  Improved tumor vascular function following high‐dose epidermal growth factor receptor tyrosine kinase inhibitor therapy , 2007, Journal of magnetic resonance imaging : JMRI.

[5]  Dai Fukumura,et al.  Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. , 2007, Microvascular research.

[6]  Tracy T Batchelor,et al.  VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. , 2007, Trends in molecular medicine.

[7]  David Zurakowski,et al.  A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. , 2006, Journal of the National Cancer Institute.

[8]  C. Hudis.  Clinical implications of antiangiogenic therapies. , 2005, Oncology.

[9]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[10]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[11]  R. Kalluri,et al.  Thrombospondin-1 Associated with Tumor Microenvironment Contributes to Low-Dose Cyclophosphamide-Mediated Endothelial Cell Apoptosis and Tumor Growth Suppression , 2004, Cancer Research.

[12]  L. Johansson,et al.  Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  A. Dicker,et al.  Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere) , 2003, International journal of cancer.

[14]  R. Weinberg,et al.  Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. , 2003, Cancer cell.

[15]  J. Henkin,et al.  Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly , 2003, Anti-cancer drugs.

[16]  R. Kerbel,et al.  Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. , 2002, Cancer research.

[17]  Edward L Schwartz,et al.  Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. , 2002, Molecular cancer therapeutics.

[18]  R. D'Amato,et al.  Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[20]  L. Xue,et al.  Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. , 1999, Cancer biotherapy & radiopharmaceuticals.

[21]  I. Fidler,et al.  Orthotopic Models are Necessary to Predict Therapy of Transplantable Tumors in Mice , 1998, Cancer and Metastasis Reviews.

[22]  G. Viale,et al.  The microtubule-affecting drug paclitaxel has antiangiogenic activity. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[24]  C. Bucana,et al.  Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells. , 1994, Journal of the National Cancer Institute.

[25]  Zhongyun Dong,et al.  Modulation of tumor cell response to chemotherapy by the organ environment , 1994, Cancer and Metastasis Reviews.

[26]  C. Bucana,et al.  Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5‐fluorouracil , 1992, International journal of cancer.

[27]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[28]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.

[29]  S. Baruchel,et al.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. , 2000, The Journal of clinical investigation.

[30]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.